AIM:The "2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease" provides recommendations to guide clinicians on the evaluation and treatment of adult patients with congenital heart disease. It incorporates new evidence to replace the "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease." METHODS:A comprehensive literature search was conducted with a focus on literature published from 2017 to 2024; in some instances, older literature was also collected and reviewed. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants and published in English were identified from MEDLINE (via PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and CINAHL for selected searches. STRUCTURE:Recommendations from the "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease" have been updated with new evidence to guide clinicians.
The IDERHA ( I ntegration of Heterogeneous D ata and E vidence towards R egulatory and H TA A cceptance) project aims to enhance medical research by establishing one of Europe’s first pan-European, disease-agnostic health data spaces. Aligned with the European Health Data Space (EHDS) principles, IDERHA addresses critical challenges in data quality, standardization, and governance, ensuring compliance with GDPR, the AI Act, and emerging EHDS regulations. Its ambition is to enable secure, federated access and analysis of health data, fostering data-driven collaboration and innovation in healthcare. IDERHA’s technical infrastructure employs a ‘privacy-by-design’ approach, leveraging federated analytics and learning to maintain data sovereignty and reduce privacy risks. The project focuses on lung cancer as a high-impact use case, utilizing AI and machine learning to improve early detection, diagnosis, and personalized care. It also aims to develop policy recommendations for the acceptance of real-world evidence (RWE) for regulatory decision-making through multi-stakeholder engagement and public consultations. However, challenges remain, including semantic interoperability, and scaling federated AI methods across borders. IDERHA’s modular, standards-based architecture and emphasis on ethical, legal, and FAIR compliance provide a robust framework for addressing these issues. By collaborating with other initiatives in the health data domain to drive compatibility, IDERHA seeks to accelerate innovation by creating a sustainable, scalable model for health data access and thereby a positive impact for patients across Europe.
AIM:The "2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes" incorporates new evidence since the "2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction" and the corresponding "2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes" and the "2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction." The "2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes" and the "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization" retire and replace, respectively, the "2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease." METHODS:A comprehensive literature search was conducted from July 2023 to April 2024. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE:Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.
Chronic coronary disease (CCD) is the leading cause of death in the United States. There is an ongoing imperative to disseminate evidence-based and patient-centered care recommendations that further align the management of patients with CCD to updated evidence-based guidelines. The writing committee developed a comprehensive CCD measure set comprising 10 performance measures and 3 quality measures, the focus of which is to include practical steps to specifically advance care in the CCD population. The measure set begins with an assessment of tobacco use and evidence-based cessation interventions. Also included are topics such as antiplatelet therapy, lipid assessment and low-density lipoprotein cholesterol goals, and guideline-directed management and therapy for hypertension and reduced left ventricular dysfunction in patients with CCD. The measure set concludes with an emphasis on the importance of cardiac rehabilitation referral and patient education, including symptom management and lifestyle modification.
